Molecular Partners AG, a clinical-stage biotech company, has announced a strategic partnership with Orano Med, a clinical-stage radiopharmaceutical company. This collaboration aims to develop a new class of targeted alpha-particle therapies using Molecular Partners' proprietary DARPin therapeutics platform. The joint effort has led to the nomination of MP0726, a Radio-DARPin candidate targeting mesothelin, for the treatment of ovarian cancer. Demonstrating promising preclinical results, this partnership combines Molecular Partners' expertise in custom-built protein drugs with Orano Med's advanced radiopharmaceutical capabilities, positioning them to address important unmet medical needs.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.